Approaches Towards Better Immunosuppressive Agents

Rong, Y.; Kiang, T. Clinical evidence on the purported pharmacokinetic interactions between corticosteroids and mycophenolic Acid. Clin. Pharmacokinet., 2023, 62(2), 157-207.
[http://dx.doi.org/10.1007/s40262-023-01212-y] [PMID: 36848031]

Sahman, M.; Mugosa, S.; Rancic, N. Utilization of mycophenolic acid, azathioprine, tacrolimus, cyclosporin, sirolimus, and everolimus: Multinational study. Front. Public Health, 2021, 9, 671316.
[http://dx.doi.org/10.3389/fpubh.2021.671316] [PMID: 33869136]

Silva, R.; Portela, R.; da Costa, I.; de Oliveira, A.; Woods, D.; de Oliveira, C.; Fonteles, M.; Beserra, M. Immunosuppressives and enteral feeding tubes: An integrative review. J. Clin. Pharm. Ther., 2020, 45(3), 408-418.
[http://dx.doi.org/10.1111/jcpt.13093] [PMID: 31854065]

Spasić, A.; Catić-Đorđević, A.; Veličković-Radovanović, R.; Stefanović, N.; Džodić, P.; Cvetković, T. Adverse effects of mycophenolic acid in renal transplant recipients: Gender differences. Int. J. Clin. Pharm., 2019, 41(3), 776-784.
[http://dx.doi.org/10.1007/s11096-019-00837-z] [PMID: 31028595]

Ponticelli, C.; Glassock, R.J. Prevention of complications from use of conventional immunosuppressants: A critical review. J. Nephrol., 2019, 32(6), 851-870.
[http://dx.doi.org/10.1007/s40620-019-00602-5] [PMID: 30927190]

Halle, M.B.; Lee, W.; Yudhistira, T.; Kim, M.; Churchill, D.G. Mycophenolic acid: Biogenesis, compound isolation, biological activity, and historical advances in total synthesis. Eur. J. Org. Chem., 2019, 2019(13), 2315-2334.
[http://dx.doi.org/10.1002/ejoc.201900245]

Wu, Q.; Li, M.; Bilal, M.; Yang, Y.; Zhang, J.; Li, X. Enhanced production of mycophenolic acid from Penicillium brevicompactumvia optimized fermentation strategy. Appl. Biochem. Biotechnol., 2022, 194(7), 3001-3015.
[http://dx.doi.org/10.1007/s12010-022-03886-9] [PMID: 35316476]

Siebert, A.; Prejs, M.; Cholewinski, G.; Dzierzbicka, K. New analogues of mycophenolic acid. Mini Rev. Med. Chem., 2017, 17(9), 734-745.
[http://dx.doi.org/10.2174/1389557516666161129160001] [PMID: 27903231]

Hedstrom, L. IMP dehydrogenase: Structure, mechanism, and inhibition. Chem. Rev., 2009, 109(7), 2903-2928.
[http://dx.doi.org/10.1021/cr900021w] [PMID: 19480389]

Beaulieu, Q.; Zhang, D.; Melki, I.; Baudouin, V.; Goldwirst, L.; Woillard, J.B.; Jacqz-Aigrain, E. Pharmacokinetics of mycophenolic acid and external evaluation of two limited sampling strategies of drug exposure in patients with juvenile systematic lupus erythematosus. Eur. J. Clin. Pharmacol., 2022, 78(6), 1003-1010.
[http://dx.doi.org/10.1007/s00228-022-03295-1] [PMID: 35294622]

Cholewiński, G.; Iwaszkiewicz-Grześ, D.; Prejs, M.; Głowacka, A.; Dzierzbicka, K. Synthesis of the inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors. J. Enzyme Inhib. Med. Chem., 2015, 30(4), 550-563.
[http://dx.doi.org/10.3109/14756366.2014.951349] [PMID: 25198892]

Pilevneli, A.D.; Ebada, S.S.; Kaşkatepe, B.; Konuklugil, B. Penicacids H–J, three new mycophenolic acid derivatives from the marine-derived fungus Rhizopus oryzae. RSC Advances, 2021, 11(55), 34938-34944.
[http://dx.doi.org/10.1039/D1RA07196C] [PMID: 35494752]

Song, X.; Tu, R.; Mei, X.; Wu, S.; Lan, B.; Zhang, L.; Luo, X.; Liu, J.; Luo, M. A mycophenolic acid derivative from the fungus Penicillium sp. SCSIO sof101. Nat. Prod. Res., 2020, 34(9), 1206-1212.
[http://dx.doi.org/10.1080/14786419.2018.1553881] [PMID: 30760051]

Iwaszkiewicz-Grzes, D.; Cholewinski, G.; Kot-Wasik, A.; Trzonkowski, P.; Dzierzbicka, K. Investigations on the immunosuppressive activity of derivatives of mycophenolic acid in immature dendritic cells. Int. Immunopharmacol., 2017, 44, 137-142.
[http://dx.doi.org/10.1016/j.intimp.2017.01.011] [PMID: 28092865]

Prejs, M.; Cholewiński, G.; Trzonkowski, P.; Kot-Wasik, A.; Dzierzbicka, K. Synthesis and antiproliferative activity of new mycophenolic acid conjugates with adenosine derivatives. J. Asian Nat. Prod. Res., 2019, 21(2), 178-185.
[PMID: 29607657]

Cholewinski, G.; Iwaszkiewicz-Grzes, D.; Trzonkowski, P.; Dzierzbicka, K. Synthesis and biological activity of ester derivatives of mycophenolic acid and acridines/acridones as potential immunosuppressive agents. J. Enzyme Inhib. Med. Chem., 2016, 31(6), 974-982.
[http://dx.doi.org/10.3109/14756366.2015.1077821] [PMID: 26308114]

Ohnuki, T.; Ejiri, M.; Kizuka, M.; Fujiwara, M.; Nishi, T. Practical one-step glucuronidation via biotransformation. Bioorg. Med. Chem. Lett., 2019, 29(2), 199-203.
[http://dx.doi.org/10.1016/j.bmcl.2018.11.056] [PMID: 30551902]

Klangjorhor, J.; Chaiyawat, P.; Teeyakasem, P.; Sirikaew, N.; Phanphaisarn, A.; Settakorn, J.; Lirdprapamongkol, K.; Yama, S.; Svasti, J.; Pruksakorn, D. Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. Int. J. Cancer, 2020, 146(12), 3397-3409.
[http://dx.doi.org/10.1002/ijc.32735] [PMID: 31609477]

Yuan, S.; Gopal, J.V.; Ren, S.; Chen, L.; Liu, L.; Gao, Z. Anticancer fungal natural products: Mechanisms of action and biosynthesis. Eur. J. Med. Chem., 2020, 202, 112502.
[http://dx.doi.org/10.1016/j.ejmech.2020.112502] [PMID: 32652407]

Naffouje, R.; Grover, P.; Yu, H.; Sendilnathan, A.; Wolfe, K.; Majd, N.; Smith, E.P.; Takeuchi, K.; Senda, T.; Kofuji, S.; Sasaki, A.T. Anti-tumor potential of IMP dehydrogenase inhibitors: A century-long story. Cancers, 2019, 11(9), 1346.
[http://dx.doi.org/10.3390/cancers11091346] [PMID: 31514446]

Valvezan, A.J.; McNamara, M.C.; Miller, S.K.; Torrence, M.E.; Asara, J.M.; Henske, E.P.; Manning, B.D. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. JCI Insight, 2020, 5(7), e135071.
[http://dx.doi.org/10.1172/jci.insight.135071] [PMID: 32271165]

Hirunsatitpron, P.; Hanprasertpong, N.; Noppakun, K.; Pruksakorn, D.; Teekachunhatean, S.; Koonrungsesomboon, N. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta‐analysis. Br. J. Clin. Pharmacol., 2022, 88(2), 476-489.
[http://dx.doi.org/10.1111/bcp.14979] [PMID: 34240462]

Benjanuwattra, J.; Chaiyawat, P.; Pruksakorn, D.; Koonrungsesomboon, N. Therapeutic potential and molecular mechanisms of mycophenolic acid as an anticancer agent. Eur. J. Pharmacol., 2020, 887, 173580.
[http://dx.doi.org/10.1016/j.ejphar.2020.173580] [PMID: 32949604]

Shah, C.P.; Kharkar, P.S. Newer human inosine 5′-monophosphate dehydrogenase 2 (h IMPDH2) inhibitors as potential anticancer agents. J. Enzyme Inhib. Med. Chem., 2018, 33(1), 972-977.
[http://dx.doi.org/10.1080/14756366.2018.1474211] [PMID: 29792360]

Khater, I.; Nassar, A. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease. Biochem. Biophys. Rep., 2021, 27, 101032.
[http://dx.doi.org/10.1016/j.bbrep.2021.101032] [PMID: 34099985]

Schoot, T.S.; Kerckhoffs, A.P.M.; Hilbrands, L.B.; van Marum, R.J. Immunosuppressive drugs and COVID-19: A review. Front. Pharmacol., 2020, 11, 1333.
[http://dx.doi.org/10.3389/fphar.2020.01333] [PMID: 32982743]

Kato, F.; Matsuyama, S.; Kawase, M.; Hishiki, T.; Katoh, H.; Takeda, M. Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2. Microbiol. Immunol., 2020, 64(9), 635-639.
[http://dx.doi.org/10.1111/1348-0421.12828] [PMID: 32579258]

Pillaiyar, T.; Meenakshisundaram, S.; Manickam, M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov. Today, 2020, 25(4), 668-688.
[http://dx.doi.org/10.1016/j.drudis.2020.01.015] [PMID: 32006468]

Shang, F.F.; Wang, M.Y.; Ai, J.P.; Shen, Q.K.; Guo, H.Y.; Jin, C-M.; Chen, F.E.; Quan, Z.S.; Jin, L.; Zhang, C. Synthesis and evaluation of mycophenolic acid derivatives as potential anti-Toxoplasma gondii agents. Med. Chem. Res., 2021, 30(12), 2228-2239.
[http://dx.doi.org/10.1007/s00044-021-02803-9]

Raza, M.; Khan, Z.; Ahmad, A.; Raza, S.; Khan, A.; Mohammadzai, I.U.; Zada, S. In silico 3-D structure prediction and molecular docking studies of inosine monophosphate dehydrogenase from Plasmodium falciparum. Comput. Biol. Chem., 2017, 71, 10-19.
[http://dx.doi.org/10.1016/j.compbiolchem.2017.09.002] [PMID: 28957725]

Chen, Z.; Fang, H.; Hua, X.; Liu, W.; Liu, Y.; Xue, C.; Wang, B.; Bazhanau, D.; Zhu, X.; Yuan, M.; Ru, J.; Chu, P. Research on crystal structure and fungicidal activity of the amide derivatives based on the natural products sinapic scid and mycophenolic acid. J. Chem., 2021, 1036199.

Ferraris, D.M.; Gelardi, E.L.M.; Garavaglia, S.; Miggiano, R.; Rizzi, M. Targeting NAD-dependent dehydrogenases in drug discovery against infectious diseases and cancer. Biochem. Soc. Trans., 2020, 48(2), 693-707.
[http://dx.doi.org/10.1042/BST20191261] [PMID: 32311017]

Sahu, N.U.; Singh, V.; Ferraris, D.M.; Rizzi, M.; Kharkar, P.S. Hit discovery of Mycobacterium tuberculosis inosine 5′-monophosphate dehydrogenase, GuaB2, inhibitors. Bioorg. Med. Chem. Lett., 2018, 28(10), 1714-1718.
[http://dx.doi.org/10.1016/j.bmcl.2018.04.045] [PMID: 29699922]

Lee, S.; Ku, A.F.; Vippila, M.R.; Wang, Y.; Zhang, M.; Wang, X.; Hedstrom, L.; Cuny, G.D. Mycophenolic anilides as broad specificity inosine-5′-monophosphate dehydrogenase (IMPDH) inhibitors. Bioorg. Med. Chem. Lett., 2020, 30(24), 127543.
[http://dx.doi.org/10.1016/j.bmcl.2020.127543] [PMID: 32931912]

Charette, A.B.; Côté, B. Stereoselective synthesis of sll four isomers of coronarme acid: A general approach to 3-methanoamino acids. J. Am. Chem. Soc., 1995, 117(51), 12721-12732.
[http://dx.doi.org/10.1021/ja00156a009]

Tang, C.; Li, Q.; Deng, X.; Wu, W.; Liao, L.; Liang, K.; Huo, R.; Li, C.; Han, J.; Tang, W.; Jiang, N. Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid. RSC Advances, 2020, 10(20), 12089-12104.
[http://dx.doi.org/10.1039/D0RA01002B] [PMID: 35496622]

Siebert, A.; Wysocka, M.; Krawczyk, B.; Cholewiński, G.; Rachoń, J. Synthesis and antimicrobial activity of amino acid and peptide derivatives of mycophenolic acid. Eur. J. Med. Chem., 2018, 143, 646-655.
[http://dx.doi.org/10.1016/j.ejmech.2017.11.094] [PMID: 29216563]

Siebert, A.; Cholewiński, G.; Trzonkowski, P.; Rachon, J. Immunosuppressive properties of amino acid and peptide derivatives of mycophenolic acid. Eur. J. Med. Chem., 2020, 189, 112091.
[http://dx.doi.org/10.1016/j.ejmech.2020.112091] [PMID: 32007665]

Felczak, K.; Vince, R.; Pankiewicz, K.W. NAD-based inhibitors with anticancer potential. Bioorg. Med. Chem. Lett., 2014, 24(1), 332-336.
[http://dx.doi.org/10.1016/j.bmcl.2013.11.005] [PMID: 24269162]

Siebert, A.; Deptuła, M.; Cichorek, M.; Ronowska, A.; Cholewiński, G.; Rachon, J. Anticancer properties of amino acid and peptide derivatives of mycophenolic acid. Anticancer. Agents Med. Chem., 2021, 21(4), 462-467.
[http://dx.doi.org/10.2174/1871520620666200516151456] [PMID: 32416705]

Tsolaki, E.; Eleftheriou, P.; Kartsev, V.; Geronikaki, A.; Saxena, A.K. Application of docking analysis in the prediction and biological evaluation of the lipoxygenase inhibitory action of thiazolyl derivatives of mycophenolic acid. Molecules, 2018, 23(7), 1621.
[http://dx.doi.org/10.3390/molecules23071621] [PMID: 29970872]

Walczak, J.M.; Iwaszkiewicz-Grześ, D.; Ziomkowska, M.; Śliwka-Kaszyńska, M.; Daśko, M.; Trzonkowski, P.; Cholewiński, G. Novel amides of mycophenolic acid and some heterocyclic derivatives as immunosuppressive agents. J. Enzyme Inhib. Med. Chem., 2022, 37(1), 2725-2741.
[http://dx.doi.org/10.1080/14756366.2022.2127701] [PMID: 36189734]

Yadav, J.P.; Lodhi, L.; Fatma, T.; Dey, K.K.; Ghosh, M. Investigation of the influence of various functional groups on the dynamics of glucocorticoids. ACS Omega, 2022, 7(47), 43190-43209.
[http://dx.doi.org/10.1021/acsomega.2c05892] [PMID: 36467925]

Jouve, R.; Thery, V.; Ducki, S.; Helfenbein, J.; Thiery, J.C.; Job, A.; Picard, E.; Mallet, C.; Ripoche, I.; Bennis, K. Optimization of the synthesis of a key intermediate for the preparation of glucocorticoids. Steroids, 2018, 137, 14-21.
[http://dx.doi.org/10.1016/j.steroids.2018.06.007] [PMID: 30017852]

Ghidini, E.; Capelli, A.M.; Carnini, C.; Cenacchi, V.; Marchini, G.; Virdis, A.; Italia, A.; Facchinetti, F. Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. Steroids, 2015, 95, 88-95.
[http://dx.doi.org/10.1016/j.steroids.2014.12.016] [PMID: 25556984]

Pan, X.; Xie, F.; Xiao, D.; Zhou, X.; Xiao, J. Design, synthesis, and renal targeting of methylprednisolone-lysozyme. Int. J. Mol. Sci., 2020, 21(6), 1922.
[http://dx.doi.org/10.3390/ijms21061922] [PMID: 32168938]

Närhi, F.; Moonesinghe, S.R.; Shenkin, S.D.; Drake, T.M.; Mulholland, R.H.; Donegan, C.; Dunning, J.; Fairfield, C.J.; Girvan, M.; Hardwick, H.E.; Ho, A.; Leeming, G.; Nguyen-Van-Tam, J.S.; Pius, R.; Russell, C.D.; Shaw, C.A.; Spencer, R.G.; Turtle, L.; Openshaw, P.J.M.; Baillie, J.K.; Harrison, E.M.; Semple, M.G.; Docherty, A.B.; Baillie, J.K.; Semple, M.G.; Openshaw, P.J.M.; Carson, G.; Alex, B.; Andrikopoulos, P.; Bach, B.; Barclay, W.S.; Bogaert, D.; Chand, M.; Chechi, K.; Cooke, G.S.; da Silva Filipe, A.; de Silva, T.; Docherty, A.B. dos Santos Correia, G¸.; Dumas, M-E.; Dunning, J.; Fletcher, T.; Green, C.A.; Greenhalf, W.; Griffin, J.; Gupta, R.K.; Harrison, E.M.; Hiscox, J.A.; Ho, A.Y.W.; Horby, P.W.; Ijaz, S.; Khoo, S.; Klenerman, P.; Law, A.; Lewis, M.; Liggi, S.; Lim, W.S.; Maslen, L.; Mentzer, A.J.; Merson, L.; Meynert, A.M.; Moore, S.C.; Noursadeghi, M.; Olanipekun, M.; Osagie, A.; Palmarini, M.; Palmieri, C.; Paxton, W.A.; Pollakis, G.; Price, N.; Rambaut, A.; Robertson, D.L.; Russell, C.D.; Sancho-Shimizu, V.; Sands, C.; Scott, J.T.; Sigfrid, L.; Solomon, T.; Sriskandan, S.; Stuart, D.; Summers, C.; Swann, O.V.; Takats, Z.; Takis, P.; Tedder, R.S.; Thompson, A.A.R.; Thomson, E.C.; Thwaites, R.S.; Turtle, L.C.W.; Zambon, M.; Hardwick, H.; Donohue, C.; Griffiths, F.; Oosthuyzen, W.; Donegan, C.; Spencer, R.G.; Norman, L.; Pius, R.; Drake, T.M.; Fairfield, C.J.; Knight, S.R.; Mclean, K.A.; Murphy, D.; Shaw, C.A.; Dalton, J.; Girvan, M.; Saviciute, E.; Roberts, S.; Harrison, J.; Marsh, L.; Connor, M.; Halpin, S.; Jackson, C.; Gamble, C.; Plotkin, D.; Lee, J.; Leeming, G.; Law, A.; Wham, M.; Clohisey, S.; Hendry, R.; Scott-Brown, J.; Shaw, V.; McDonald, S.E.; Keating, S.; Ahmed, K.A.; Armstrong, J.A.; Ashworth, M.; Asiimwe, I.G.; Bakshi, S.; Barlow, S.L.; Booth, L.; Brennan, B.; Bullock, K.; Catterall, B.W.A.; Clark, J.J.; Clarke, E.A.; Cole, S.; Cooper, L.; Cox, H.; Davis, C.; Dincarslan, O.; Dunn, C.; Dyer, P.; Elliott, A.; Evans, A.; Finch, L.; Fisher, L.W.S.; Foster, T.; Garcia-Dorival, I.; Gunning, P.; Hartley, C.; Jensen, R.L.; Jones, C.B.; Jones, T.R.; Khandaker, S.; King, K.; Kiy, R.T.; Koukorava, C.; Lake, A.; Lant, S.; Latawiec, D.; Lavelle-Langham, L.; Lefteri, D.; Lett, L.; Livoti, L.A.; Mancini, M.; McDonald, S.; McEvoy, L.; McLauchlan, J.; Metelmann, S.; Miah, N.S.; Middleton, J.; Mitchell, J.; Moore, S.C.; Murphy, E.G.; Penrice-Randal, R.; Pilgrim, J.; Prince, T.; Reynolds, W.; Ridley, P.M.; Sales, D.; Shaw, V.E.; Shears, R.K.; Small, B.; Subramaniam, K.S.; Szemiel, A.; Taggart, A.; Tanianis-Hughes, J.; Thomas, J.; Trochu, E.; van Tonder, L.; Wilcock, E.; Zhang, J.E.; Flaherty, L.; Maziere, N.; Cass, E.; Doce Carracedo, A.; Carlucci, N.; Holmes, A.; Massey, H.; Murphy, L.; McCafferty, S.; Clark, R.; Fawkes, A.; Morrice, K.; Maclean, A.; Wrobel, N.; Donelly, L.; Coutts, A.; Hafezi, K.; MacGillivray, L.; Gilchrist, T.; Adeniji, K.; Agranoff, D.; Agwuh, K.; Ail, D.; Aldera, E.L.; Alegria, A.; Allen, S.; Angus, B.; Ashish, A.; Atkinson, D.; Bari, S.; Barlow, G.; Barnass, S.; Barrett, N.; Bassford, C.; Basude, S.; Baxter, D.; Beadsworth, M.; Bernatoniene, J.; Berridge, J.; Berry, C.; Best, N.; Bothma, P.; Chadwick, D.; Brittain-Long, R.; Bulteel, N.; Burden, T.; Burtenshaw, A.; Caruth, V.; Chadwick, D.; Chambler, D.; Chee, N.; Child, J.; Chukkambotla, S.; Clark, T.; Collini, P.; Cosgrove, C.; Cupitt, J.; Cutino-Moguel, M-T.; Dark, P.; Dawson, C.; Dervisevic, S.; Donnison, P.; Douthwaite, S.; Drummond, A.; DuRand, I.; Dushianthan, A.; Dyer, T.; Evans, C.; Eziefula, C.; Fegan, C.; Finn, A.; Fullerton, D.; Garg, S.; Garg, S.; Garg, A.; Gkrania-Klotsas, E.; Godden, J.; Goldsmith, A.; Graham, C.; Hardy, E.; Hartshorn, S.; Harvey, D.; Havalda, P.; Hawcutt, D.B.; Hobrok, M.; Hodgson, L.; Hormis, A.; Jacobs, M.; Jain, S.; Jennings, P.; Kaliappan, A.; Kasipandian, V.; Kegg, S.; Kelsey, M.; Kendall, J.; Kerrison, C.; Kerslake, I.; Koch, O.; Koduri, G.; Koshy, G.; Laha, S.; Laird, S.; Larkin, S.; Leiner, T.; Lillie, P.; Limb, J.; Linnett, V.; Little, J.; Lyttle, M.; MacMahon, M.; MacNaughton, E.; Mankregod, R.; Masson, H.; Matovu, E.; McCullough, K.; McEwen, R.; Meda, M.; Mills, G.; Minton, J.; Mirfenderesky, M.; Mohandas, K.; Mok, Q.; Moon, J.; Moore, E.; Morgan, P.; Morris, C.; Mortimore, K.; Moses, S.; Mpenge, M.; Mulla, R.; Murphy, M.; Nagel, M.; Nagarajan, T.; Nelson, M.; Norris, L.; O’Shea, M.K.; Otahal, I.; Ostermann, M.; Pais, M.; Palmieri, C.; Panchatsharam, S.; Papakonstantinou, D.; Paraiso, H.; Patel, B.; Pattison, N.; Pepperell, J.; Peters, M.; Phull, M.; Pintus, S.; Singh Pooni, J.; Planche, T.; Post, F.; Price, D.; Prout, R.; Rae, N.; Reschreiter, H.; Reynolds, T.; Richardson, N.; Roberts, M.; Roberts, D.; Rose, A.; Rousseau, G.; Ruge, B.; Ryan, B.; Saluja, T.; Schmid, M.; Shah, A.; Shanmuga, P.; Sharma, A.; Shawcross, A.; Sizer, J.; Shankar-Hari, M.; Smith, R.; Snelson, C.; Spittle, N.; Staines, N.; Stambach, T.; Stewart, R.; Subudhi, P.; Szakmany, T.; Tatham, K.; Thomas, J.; Thompson, C.; Thompson, R.; Tridente, A.; Tupper-Carey, D.; Twagira, M.; Vallotton, N.; Vancheeswaran, R.; Vincent-Smith, L.; Visuvanathan, S.; Vuylsteke, A.; Waddy, S.; Wake, R.; Walden, A.; Welters, I.; Whitehouse, T.; Whittaker, P.; Whittington, A.; Papineni, P.; Wijesinghe, M.; Williams, M.; Wilson, L.; Sarah, S.; Winchester, S.; Wiselka, M.; Wolverson, A.; Wootton, D.G.; Workman, A.; Yates, B.; Young, P. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO clinical characterisation protocol UK: Prospective, cohort study. Lancet Digit. Health, 2022, 4(4), e220-e234.
[http://dx.doi.org/10.1016/S2589-7500(22)00018-8] [PMID: 35337642]

Ebrahimi Chaharom, F.; Pourafkari, L.; Ebrahimi Chaharom, A.A.; Nader, N.D. Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes. Pulm. Pharmacol. Ther., 2022, 72, 102107.
[http://dx.doi.org/10.1016/j.pupt.2021.102107] [PMID: 34933068]

Mehta, J.; Rolta, R.; Mehta, B.B.; Kaushik, N.; Choi, E.H.; Kaushik, N.K. Role of dexamethasone and methylprednisolone corticosteroids in coronavirus disease 2019 hospitalized patients: A review. Front. Microbiol., 2022, 13, 813358.
[http://dx.doi.org/10.3389/fmicb.2022.813358] [PMID: 35242118]

Tiwari, G.; Chauhan, M.S.; Sharma, D. Systematic in silico studies of corticosteroids and its binding affinities with glucocorticoid receptor for covid-19 treatment: Ab-initio, molecular docking and MD simulation studies. Polycycl. Aromat. Compd., 2023, 43(5), 4654-4669.
[http://dx.doi.org/10.1080/10406638.2022.2092878] [http://dx.doi.org/10.1080/10406638.2022.2092878]

Khan, M.O.F.; Park, K.K.; Lee, H.J. Antedrugs: An approach to safer drugs. Curr. Med. Chem., 2005, 12(19), 2227-2239.
[http://dx.doi.org/10.2174/0929867054864840] [PMID: 16178782]

Moss, G.P. Nomenclature of steroids (Recommendations 1989). Pure Appl. Chem., 1989, 61(10), 1783-1822.
[http://dx.doi.org/10.1351/pac198961101783]

Fernández-Cabezón, L.; Galán, B.; García, J.L. New insights on steroids biotechnology. Front. Microbiol., 2018, 9, 958.
[http://dx.doi.org/10.3389/fmicb.2018.00958] [PMID: 29867863]

Costa, S.; Zappaterra, F.; Summa, D.; Semeraro, B.; Fantin, G. ∆1-Dehydrogenation and C20 reduction of cortisone and hydrocortisone catalyzed by Rhodococcus Strains. Molecules, 2020, 25(9), 2192.
[http://dx.doi.org/10.3390/molecules25092192] [PMID: 32392887]

Herráiz, I. Chemical pathways of corticosteroids, industrial synthesis from sapogenins. In: Microbial Steroids. Methods in Molecular Biology; Barredo, J.L.; Herráiz, I., Eds.; Humana Press: New York, 2017; pp. 15-27.
[http://dx.doi.org/10.1007/978-1-4939-7183-1_2]

Bowers, A.; Ringold, H.J. Steroids. XCV. 1 Synthesis of 6α-Methyl-21-desoxycortisone. A new route to 6α-Methylcortisone. J. Am. Chem. Soc., 1958, 80(12), 3091-3093.
[http://dx.doi.org/10.1021/ja01545a047]

Vardanyan, R.S.; Hruby, V.J. Corticosteroids. In: Synthesis of Essential Drugs; Elsevier, 2006; pp. 349-363.
[http://dx.doi.org/10.1016/B978-044452166-8/50027-3]

Walker, M.C.; Chang, M.C.Y. Natural and engineered biosynthesis of fluorinated natural products. Chem. Soc. Rev., 2014, 43(18), 6527-6536.
[http://dx.doi.org/10.1039/C4CS00027G] [PMID: 24776946]

Rahman, M.; Anjum, F. Fludrocortisone. In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2023.

Baymeeva, N.V.; Platova, A.I.; Miroshnichenko, I.I.; Belovolov, A.Y.; Gladkikh, V.D.; Tatarinov, A.M. High performance liquid chromatography/mass spectrometry method for quantitative determination of fludrocortisone in human blood plasma. Pharm. Chem. J., 2021, 55(5), 510-515.
[http://dx.doi.org/10.1007/s11094-021-02453-6]

Cooper, M.S.; Stewart, P.M. 11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J. Clin. Endocrinol. Metab., 2009, 94(12), 4645-4654.
[http://dx.doi.org/10.1210/jc.2009-1412] [PMID: 19837912]

Drug Bank 2023. Available from: https://go.drugbank.com/drugs/DB00860

Irwin, J.B.; Baldwin, A.L.; Stenberg, V.I. General theory of inflammation: Patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity. J. Inflamm. Res., 2019, 12, 161-166.
[http://dx.doi.org/10.2147/JIR.S195165] [PMID: 31354330]

Toehwé, L.H.; Prado, L.D.; Rocha, H.V.A. Prednisone raw material characterization and formulation development. Braz. J. Pharm. Sci., 2017, 53(4), e00088.

Henry, A.; Mahajan, A.; Crowther, C.A.; Lainchbury, A.; Roberts, L.; Shand, A.W.; Welsh, A.W. Short-term effects of dexamethasone versus betamethasone on ultrasonic measures of fetal well-being: Cohort from a blinded, randomized trial. Fetal Diagn. Ther., 2021, 48(7), 526-540.
[http://dx.doi.org/10.1159/000517623] [PMID: 34350865]

Jobe, A.H.; Milad, M.A.; Peppard, T.; Jusko, W.J. Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India. Clin. Transl. Sci., 2020, 13(2), 391-399.
[http://dx.doi.org/10.1111/cts.12724] [PMID: 31808984]

Issa, A.K.; Taha, W.S.; Elsayeh, A.A.; Elhadad, H.K. Comparative study between betamethasone and dexamethasone as a prophylactic corticosteroids therapy on neonatal outcome in elective cesarean section at 37 weeks. Egypt. J. Hosp. Med., 2019, 74(2), 420-427.
[http://dx.doi.org/10.21608/ejhm.2019.23108]

Wang, S.; Shi, Y.; Tian, W. A formal synthesis of betamethasone. Chin. J. Chem., 2015, 33(6), 637-642.
[http://dx.doi.org/10.1002/cjoc.201500335]

Tang, J.; Liu, X.; Zeng, C.; Meng, H.; Tian, M.; Guo, C. A novel route for the preparation of betamethasone from 9α-hydroxy-androst-4-ene-3,17-dione (9αOH-AD) by chemical synthesis and fermentation. J. Chem. Res., 2017, 41(5), 266-270.
[http://dx.doi.org/10.3184/174751917X14925986241025]

Edwards, J.A.; Ringold, H.J.; Djerassi, C. Steroids. CXXXVI. Synthesis of a new class of potent cortical hormones. 6α-Fluoro- and 6α,9β-difluoro-16α-methylprednisolone and related steroids. J. Am. Chem. Soc., 1960, 82(9), 2318-2322.
[http://dx.doi.org/10.1021/ja01494a054]

Henbest, H.B.; Wrigley, T.I. 960. Aspects of stereochemistry. Part IX. The formation of fluorohydrins from the cholesterol 5: 6-epoxides and boron trifluoride–ether complex. J. Chem. Soc., 1957, 0(0), 4765-4768.
[http://dx.doi.org/10.1039/JR9570004765]

Biggadike, K. Fluticasone furoate/fluticasone propionate - different drugs with different properties. Clin. Respir. J., 2011, 5(3), 183-184.
[http://dx.doi.org/10.1111/j.1752-699X.2011.00244.x] [PMID: 21569222]

Solanki, K.; Bavadia, R.Z.; Patel, D.P.; Patel, D.J.; Shah, T.C.; Singh, M.K. Process for preparing fluticasone propionate/furoate. W.O. Patent 2012029077A2, 2011.

Chu, D.; Ji, H.; Hong, X. Method for preparing fluticasone furoate. U.S. Patent 8969547 B2, 2013.

Zhou, J.; Jin, C.; Su, W. Improved synthesis of fluticasone propionate. Org. Process Res. Dev., 2014, 18(8), 928-933.
[http://dx.doi.org/10.1021/op5001226]

Biggadike, K.; Bledsoe, R.K.; Hassell, A.M.; Kirk, B.E.; McLay, I.M.; Shewchuk, L.M.; Stewart, E.L. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem., 2008, 51(12), 3349-3352.
[http://dx.doi.org/10.1021/jm800279t] [PMID: 18522385]

Kandula, V.R.; Shaikh, L.; Samanta, G. Utilization of quality by design, kinetic modeling, and computational fluid dynamics for process optimization and scale-up. Org. Process Res. Dev., 2023, 27(5), 875-889.
[http://dx.doi.org/10.1021/acs.oprd.3c00015]

Lenna, R.; Montoro, M. Process for preparing budesonide. US 8119793 B2, 2008.

Phull, M.S.; Jadav, S.S.; Bohara, C.S.; Gundla, R.; Mainkar, P.S. Continuous flow process for preparing budesonide. J. Flow Chem., 2022, 12(2), 237-246.
[http://dx.doi.org/10.1007/s41981-022-00221-5] [PMID: 35465101]

Restaino, O.F.; Barbuto Ferraiuolo, S.; Perna, A.; Cammarota, M.; Borzacchiello, M.G.; Fiorentino, A.; Schiraldi, C. Biotechnological transformation of hydrocortisone into 16α- hydroxyprednisolone by coupling Arthrobacter simplex and Streptomyces roseochromogenes. Molecules, 2020, 25(21), 4912.
[http://dx.doi.org/10.3390/molecules25214912] [PMID: 33114231]

Ghidini, E.; Marchini, G.; Capelli, A.M.; Carnini, C.; Cenacchi, V.; Fioni, A.; Facchinetti, F.; Rancati, F. Novel pyrrolidine derivatives of budesonide as long acting inhaled corticosteroids for the treatment of pulmonary inflammatory diseases. J. Med. Chem., 2018, 61(11), 4757-4773.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01873] [PMID: 29741897]

Yan, Y.; Wang, P.; Li, R.; Sun, Y.; Zhang, R.; Huo, C.; Xing, J.; Dong, Y. Synthesis of budesonide conjugates and their anti-inflammatory effects: A preliminary study. Drug Des. Devel. Ther., 2019, 13, 681-694.
[http://dx.doi.org/10.2147/DDDT.S192348] [PMID: 30858698]

Kowalczyk, A.; Pieczonka, A.; Rachwalski, M.; Leśniak, S.; Stączek, P. Synthesis and evaluation of biological activities of aziridine derivatives of urea and thiourea. Molecules, 2017, 23(1), 45.
[http://dx.doi.org/10.3390/molecules23010045] [PMID: 29295572]

Sachdeva, H.; Khaturia, S.; Saquib, M.; Khatik, N.; Khandelwal, A.R.; Meena, R.; Sharma, K. Oxygen- and sulphur-containing heterocyclic compounds as potential anticancer agents. Appl. Biochem. Biotechnol., 2022, 194(12), 6438-6467.
[http://dx.doi.org/10.1007/s12010-022-04099-w] [PMID: 35900713]

Pathania, S.; Narang, R.K.; Rawal, R.K. Role of sulphur-heterocycles in medicinal chemistry: An update. Eur. J. Med. Chem., 2019, 180, 486-508.
[http://dx.doi.org/10.1016/j.ejmech.2019.07.043] [PMID: 31330449]

Parmar, D.R.; Soni, J.Y.; Guduru, R.; Rayani, R.H.; Kusurkar, R.V.; Vala, A.G. Azetidines of pharmacological interest. Arch. Pharm., 2021, 354(11), 2100062.
[http://dx.doi.org/10.1002/ardp.202100062] [PMID: 34184778]

Niu, Z.X.; Wang, Y.T.; Zhang, S.N.; Li, Y.; Chen, X.B.; Wang, S.Q.; Liu, H.M. Application and synthesis of thiazole ring in clinically approved drugs. Eur. J. Med. Chem., 2023, 250, 115172.
[http://dx.doi.org/10.1016/j.ejmech.2023.115172] [PMID: 36758304]

Sprangers, B.; Pirenne, J.; Mathieu, C.; Waer, M. Other Forms of Immunosuppression; Kidney Transplantation - Principles and Practice, 2019, pp. 313-332.

Hussain, Y.; Khan, H. Immunosuppressive Drugs; Encyclopedia of Infection and Immunity., 2022, pp. 726-740.

Humble, R.W.; Middleton, D.F.; Banoub, J.; Ewing, D.F.; Boa, A.N.; Mackenzie, G. A synthesis of bredinin (Mizoribine®) from an acyclic precursor. Tetrahedron Lett., 2011, 52(47), 6223-6227.
[http://dx.doi.org/10.1016/j.tetlet.2011.09.085]

D'Errico, S.; Oliviero, G.; Borbone, N.; Piccialli, V.; Piccialli, G. Synthesis of 5-Aminoimidazole-4-Carboxamide Riboside (AICAR) and its derivatives using inosine as starting material. Curr. Protoc. Nucleic Acid. Chem., 2015, 63, 1.35.1-1.35.24.
[http://dx.doi.org/10.1002/0471142700.nc0135s63]

Haq, M.; Adnan, G. Ruxolitinib; StatPearls Publishing: Treasure Island, FL, 2023.

Parlakpinar, H.; Gunata, M. Transplantation and immunosuppression: A review of novel transplant-related immunosuppressant drugs. Immunopharmacol. Immunotoxicol., 2021, 43(6), 651-665.
[http://dx.doi.org/10.1080/08923973.2021.1966033] [PMID: 34415233]

Kocienski, P. Synthesis of (R)-Ruxolitinib. Synfacts, 2015, 11(9), 0907.
[http://dx.doi.org/10.1055/s-0034-1378766]

Alamri, R.D.; Elmeligy, M.A.; Albalawi, G.A.; Alquayr, S.M.; Alsubhi, S.S.; El-Ghaiesh, S.H. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review. Int. Immunopharmacol., 2021, 93, 107398.
[http://dx.doi.org/10.1016/j.intimp.2021.107398] [PMID: 33571819]

Ramakrishnan, A.; Gobind, K. Unichem Laboratories Limited, applicant. An improved process for preparation of leflunomide. W.O. Patent 2007086076A2, 2007.

Strasser, D.S.; Froidevaux, S.; Sippel, V.; Gerossier, E.; Grieder, U.; Pierlot, G.M.; Kieninger-Graefitsch, A.; Vezzali, E.; Stalder, A.K.; Renault, B.; Ryge, J.; Hart, A.; Mentzel, U.; Groenen, P.M.A.; Keller, M.P.; Trendelenburg, M.; Martinic, M.M.; Murphy, M.J. Preclinical to clinical translation of cenerimod, a novel S1P 1 receptor modulator, in systemic lupus erythematosus. RMD Open, 2020, 6(2), e001261.
[http://dx.doi.org/10.1136/rmdopen-2020-001261] [PMID: 32917831]

Idorsia initiates OPUS a phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus Allschwil (CH): Idorsia Pharmaceuticals 2022. Available from: https://www.idorsia.com/media/news-details?newsId=2895813

Schmidt, G.; Bolli, M.H.; Lescop, C.; Abele, S. Practical synthesis of a S1P receptor 1 agonist via a guareschi–thorpe reaction. Org. Process Res. Dev., 2016, 20(9), 1637-1646.
[http://dx.doi.org/10.1021/acs.oprd.6b00210]

Kim, Y.R.; Kim, J.S.; Gu, S.J.; Jo, S.; Kim, S.; Young Kim, S.; Lee, D.; Jang, K.; Choo, H.; Kim, T.H.; Jung, J.U.; Min, S.J.; Yang, C.S. Identification of highly potent and selective inhibitor, TIPTP, of the p22phox-Rubicon axis as a therapeutic agent for rheumatoid arthritis. Sci. Rep., 2020, 10(1), 4570.
[http://dx.doi.org/10.1038/s41598-020-61630-x] [PMID: 32165681]

Gartlan, K.H.; Jaiswal, J.K.; Bull, M.R.; Akhlaghi, H.; Sutton, V.R.; Alexander, K.A.; Chang, K.; Hill, G.R.; Miller, C.K.; O’Connor, P.D.; Jose, J.; Trapani, J.A.; Charman, S.A.; Spicer, J.A.; Jamieson, S.M.F. Preclinical activity and pharmacokinetic/pharmacodynamic relationship for a series of novel benzenesulfonamide perforin inhibitors. ACS Pharmacol. Transl. Sci., 2022, 5(6), 429-439.
[http://dx.doi.org/10.1021/acsptsci.2c00009] [PMID: 35711815]

Spicer, J.A.; Miller, C.K.; O’Connor, P.D.; Jose, J.; Huttunen, K.M.; Jaiswal, J.K.; Denny, W.A.; Akhlaghi, H.; Browne, K.A.; Trapani, J.A. Benzenesulphonamide inhibitors of the cytolytic protein perforin. Bioorg. Med. Chem. Lett., 2017, 27(4), 1050-1054.
[http://dx.doi.org/10.1016/j.bmcl.2016.12.057] [PMID: 28110869]

Hauser, S.L.; Cree, B.A.C. Treatment of multiple sclerosis: A review. Am. J. Med., 2020, 133(12), 1380-1390.e2.
[http://dx.doi.org/10.1016/j.amjmed.2020.05.049] [PMID: 32682869]

Montalban, X.; Wallace, D.; Genovese, M.C.; Tomic, D.; Parsons-Rich, D.; Le Bolay, C.; Kao, A.H.; Guehring, H. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: An integrated safety analysis. J. Neurol. Neurosurg. Psychiatry, 2023, 94(1), 1-9.
[http://dx.doi.org/10.1136/jnnp-2022-328799] [PMID: 36418156]

Caldwell, R.D.; Qiu, H.; Askew, B.C.; Bender, A.T.; Brugger, N.; Camps, M.; Dhanabal, M.; Dutt, V.; Eichhorn, T.; Gardberg, A.S.; Goutopoulos, A.; Grenningloh, R.; Head, J.; Healey, B.; Hodous, B.L.; Huck, B.R.; Johnson, T.L.; Jones, C.; Jones, R.C.; Mochalkin, I.; Morandi, F.; Nguyen, N.; Meyring, M.; Potnick, J.R.; Santos, D.C.; Schmidt, R.; Sherer, B.; Shutes, A.; Urbahns, K.; Follis, A.V.; Wegener, A.A.; Zimmerli, S.C.; Liu-Bujalski, L. Discovery of evobrutinib: An oral, potent, and highly selective, covalent bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J. Med. Chem., 2019, 62(17), 7643-7655.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00794] [PMID: 31368705]

Russomanno, P.; Assoni, G.; Amato, J.; D’Amore, V.M.; Scaglia, R.; Brancaccio, D.; Pedrini, M.; Polcaro, G.; La Pietra, V.; Orlando, P.; Falzoni, M.; Cerofolini, L.; Giuntini, S.; Fragai, M.; Pagano, B.; Donati, G.; Novellino, E.; Quintavalle, C.; Condorelli, G.; Sabbatino, F.; Seneci, P.; Arosio, D.; Pepe, S.; Marinelli, L. Interfering with the tumor–immune interface: Making way for triazine-based small molecules as novel PD-L1 inhibitors. J. Med. Chem., 2021, 64(21), 16020-16045.
[http://dx.doi.org/10.1021/acs.jmedchem.1c01409] [PMID: 34670084]

Pope, J.E.; Denton, C.P.; Johnson, S.R.; Fernandez-Codina, A.; Hudson, M.; Nevskaya, T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat. Rev. Rheumatol., 2023, 19(4), 212-226.
[http://dx.doi.org/10.1038/s41584-023-00909-5] [PMID: 36849541]

Aung, W.W.; Wang, C.; Xibei, J.; Horii, M.; Mizumaki, K.; Kano, M.; Okamura, A.; Kobayashi, T.; Matsushita, T. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. J. Dermatol. Sci., 2021, 101(3), 174-184.
[http://dx.doi.org/10.1016/j.jdermsci.2020.12.007] [PMID: 33451905]

Cole, M.A.; Quan, T.; Voorhees, J.J.; Fisher, G.J. Extracellular matrix regulation of fibroblast function: Redefining our perspective on skin aging. J. Cell Commun. Signal., 2018, 12(1), 35-43.
[http://dx.doi.org/10.1007/s12079-018-0459-1] [PMID: 29455303]

Mane, K.D.; Kamble, R.B.; Suryavanshi, G. Short enantioselective total synthesis of (+)-tofacitinib. Tetrahedron Lett., 2021, 67, 152838.
[http://dx.doi.org/10.1016/j.tetlet.2021.152838]

Pohlmeyer, C.W.; Shang, C.; Han, P.; Cui, Z.H.; Jones, R.M.; Clarke, A.S.; Murray, B.P.; Lopez, D.A.; Newstrom, D.W.; Inzunza, M.D.; Matzkies, F.G.; Currie, K.S.; Di Paolo, J.A. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis. BMC Rheumatol., 2021, 5(1), 15.
[http://dx.doi.org/10.1186/s41927-021-00178-3] [PMID: 33781343]

Kocienski, P. Synthesis of Lanraplenib. Synfacts, 2020, 16(7), 0764.
[http://dx.doi.org/10.1055/s-0040-1707018]

Lai, Y.; Luo, X.Y.; Guo, H.J.; Wang, S.Y.; Xiong, J.; Yang, S.X.; Li, L.M.; Zou, Q.; Mo, C.F.; Wang, Y.T.; Liu, Y. PO‐322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity. Br. J. Pharmacol., 2020, 177(7), 1666-1676.
[http://dx.doi.org/10.1111/bph.14926] [PMID: 31724152]

Lang, F.; Shumilina, E. Regulation of ion channels by the serum‐ and glucocorticoid‐inducible kinase SGK1. FASEB J., 2013, 27(1), 3-12.
[http://dx.doi.org/10.1096/fj.12-218230] [PMID: 23012321]

Wang, S.; Yuan, X.H.; Wang, S.Q.; Zhao, W.; Chen, X.B.; Yu, B. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. Eur. J. Med. Chem., 2021, 214, 113218.
[http://dx.doi.org/10.1016/j.ejmech.2021.113218] [PMID: 33540357]

Thomas, S.M.; Grandis, J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev., 2004, 30(3), 255-268.
[http://dx.doi.org/10.1016/j.ctrv.2003.10.003] [PMID: 15059649]

EGFR gene - Epidermal growth factor receptor. In: Rehovot (IL): GeneCards; The Human Gene Database., 2023.

Zhao, Y.; Qian, Y.; Sun, Z.; Shen, X.; Cai, Y.; Li, L.; Wang, Z. Role of PI3K in the progression and regression of atherosclerosis. Front. Pharmacol., 2021, 12, 632378.
[http://dx.doi.org/10.3389/fphar.2021.632378] [PMID: 33767629]

PIK3CA gene - Phosphatidylinositol-4,5-Bisphosphate 3-Kinase catalytic subunit alpha. In: Rehovot (IL): GeneCards; The Human Gene Database, 2023.

Nemat, A.; Iqbal, M.; Mehmood, T. A comprehensive review of synthesized derivatives of methotrexate in relation to their anticancer potential. J. Med. Oncl. Ther., 2020, 5(1), 4-20.
[http://dx.doi.org/10.35841/medical-oncology.5.1.4-20]

Fernández-Villa, D.; Ramírez-Jiménez, R.A.; Aranaz, I.; Acosta, N.; Vázquez-Lasa, B.; Rojo, L. Development of methotrexate complexes endowed with new biological properties envisioned for musculoskeletal regeneration in rheumatoid arthritis environments. Int. J. Mol. Sci., 2022, 23(17), 10054.
[http://dx.doi.org/10.3390/ijms231710054] [PMID: 36077450]

Conneely, S.E.; Cooper, S.L.; Rau, R.E. Use of allopurinol to mitigate 6-mercaptopurine associated gastrointestinal toxicity in acute lymphoblastic leukemia. Front. Oncol., 2020, 10, 1129.
[http://dx.doi.org/10.3389/fonc.2020.01129] [PMID: 32766146]

Toksvang, L.N.; Lee, S.H.R.; Yang, J.J.; Schmiegelow, K. Maintenance therapy for acute lymphoblastic leukemia: Basic science and clinical translations. Leukemia, 2022, 36(7), 1749-1758.
[http://dx.doi.org/10.1038/s41375-022-01591-4] [PMID: 35654820]

Aseman, M.D.; Aryamanesh, S.; Shojaeifard, Z.; Hemmateenejad, B.; Nabavizadeh, S.M. Cycloplatinated(II) derivatives of mercaptopurine capable of binding interactions with HSA/DNA. Inorg. Chem., 2019, 58(23), 16154-16170.
[http://dx.doi.org/10.1021/acs.inorgchem.9b02696] [PMID: 31721562]

Siwach, A.; Verma, P.K. Synthesis and therapeutic potential of imidazole containing compounds. BMC Chem., 2021, 15(1), 12.
[http://dx.doi.org/10.1186/s13065-020-00730-1] [PMID: 33602331]

Lazarević, S.; Đanic, M.; Al-Salami, H.; Mooranian, A.; Mikov, M. Gut microbiota metabolism of azathioprine: A new hallmark for personalized drug-targeted therapy of chronic inflammatory bowel disease. Front. Pharmacol., 2022, 13, 879170.
[http://dx.doi.org/10.3389/fphar.2022.879170] [PMID: 35450035]

Bunea, M.C.; Diculescu, V.C.; Enculescu, M.; Iovu, H.; Enache, T.A. Redox mechanism of azathioprine and its interaction with DNA. Int. J. Mol. Sci., 2021, 22(13), 6805.
[http://dx.doi.org/10.3390/ijms22136805] [PMID: 34202734]

Kennedy, N.A.; Rhatigan, E.; Arnott, I.D.R.; Noble, C.L.; Shand, A.G.; Satsangi, J.; Lees, C.W. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: An observational study, systematic review and meta‐analysis. Aliment. Pharmacol. Ther., 2013, 38(10), 1255-1266.
[http://dx.doi.org/10.1111/apt.12511] [PMID: 24117596]

Falcón, C.R.; Hurst, N.F.; Vivinetto, A.L.; López, P.H.H.; Zurita, A.; Gatti, G.; Cervi, L.; Monferran, C.G.; Roth, G.A. Diazepam impairs innate and adaptive immune responses and ameliorates experimental autoimmune encephalomyelitis. Front. Immunol., 2021, 12, 682612.
[http://dx.doi.org/10.3389/fimmu.2021.682612] [PMID: 34354703]

Daugherty, D.J.; Selvaraj, V.; Chechneva, O.V.; Liu, X.B.; Pleasure, D.E.; Deng, W. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol. Med., 2013, 5(6), 891-903.
[http://dx.doi.org/10.1002/emmm.201202124] [PMID: 23681668]

Zhao, Y.Y.; Yu, J.Z.; Li, Q.Y.; Ma, C.G.; Lu, C.Z.; Xiao, B.G. TSPO-specific ligand Vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol., 2011, 7(2-4), 187-197.
[http://dx.doi.org/10.1017/S1740925X12000129] [PMID: 22874716]

Nicholas, R.J.; McGuire, M.A.; Hyun, S.H.; Cullison, M.N.; Thompson, D.H. Development of an efficient, high purity continuous flow synthesis of diazepam. Front. Chem. Eng., 2022, 4, 877498.
[http://dx.doi.org/10.3389/fceng.2022.877498]